December 15th, 2015

Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen wins U.S. approval of long acting multiple sclerosis drug

[Reuters] – U.S. health regulators on Friday approved Biogen Idec Inc’s Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling Avonex treatment. The … Read more . . . → Read More: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen wins U.S. approval of long acting multiple sclerosis drug Similar Articles: Biogen Idec Inc (NASDAQ:BIIB) | ISIS Pharmaceuticals’ and Biogen idec’s innovative collaboration voted breakthrough alliance of 2014 Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – UPDATE 2-Biogen profit rises as new multiple sclerosis drug shines Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.